Xospata, orgilteritinib fumarate tablets, an innovative cancer treatment produced by multinational pharmaceutical Astellas Pharma, was officially prescribed to Chinese patients on Friday, thanks to the distribution network and commercialization platform of Qingdao Baheal Medical.

The drug is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.

The two companies reached an agreement last December to jointly introduce the drug to China's market, seeing the unmet medical demand. The drug was officially approved by Chinese health authorities for market launch in February.

Currently, the drug has also become available in more than 36 direct-to-patient pharmacies in 26 provinces and municipalities.